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Mouse B lymphocytes can bind soluble immune complexes by means of two 
operationally distinct  membrane receptors,  one  specific for the  Fc portion of 
the antibody molecules aggregated by the antigen (1,  2), and the other specific 
for  complement molecules,  presumably C3-derived  (3).  Membrane  receptors 
with similar properties have been found on macrophages, granulocytes, mono- 
cytes, and platelets (4-7). There is suggestive evidence that these receptors for 
complement and immunoglobulin play a primary role in the initiation of phago- 
cytosis (8-13)  and,  in  some circumstances,  in  the  triggering of the  release of 
vasoactive amines from platelets (14,  15) and of lysozomal enzymes from granu- 
locytes (16,  17).  The functions of the receptors on lymphocytes are less clear. 
The receptors may promote the follicular localization  of antigen in lymphoid 
organs  (18,  19),  be  instrumental  in  the  induction  of  the  cytotoxicity of  B 
lymphocytes for antibody-coated target cells (20-22),  or perhaps,  as recently 
proposed, play a role in the initiation of the immune response (23).1 
Soluble immune complexes, prepared with ~25I-labeled bovine serum albumin 
(BSA),  2 antiserum to BSA,  and mouse complement bind to lymphocytes pri- 
marily  through  the  complement  receptor.  The  complexes  are  seen  in  auto: 
radiographs  to  accumulate  at one pole of the  cells,  and  are neither  shed nor 
interiorized if the cells are suspended in tissue culture medium for several hours 
at 37°C  (24).  We now report a  new finding:  the membrane-bound complexes 
can be released from the cells by means of a complement-dependent mechanism, 
involving the alternate, or properdin, pathway (25-29)  of complement utiliza- 
tion. 
* Supported by National Institutes  of Health grants AI08499 and AIl1028. 
Recipients of  National  Institutes  of  Health  Postdoctoral  Fellowships AI00392 and 
GM00127. 
1  Dukor, P.,  G. Schumann, R. H.  Gisler, M.  Dierich, W.  KSnig, U. Hadding, and D. 
Bitter-Suermann. 1973. Complement-derived B cell activation by cobra venom factor and 
other mitogens? Manuscript submitted for publication. 
2 Abbreviations used in this paper: BSA, bovine serum albumin;  C3ina, C3 inactivator; 
C3PA, C3 proactivator;  CVF, cobra venom factor; EA,  antibody-sensitized erythroeytes; 
EGTA, ethyleneglycol-bis-(/3-aminoethyl  ether)N,N'-tetraaeetic  acid; KAF,  conglutinogen 
activating factor; PBS, phosphate-buffered saline. 
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Malerials and Methods 
Malerials.--CF1 mice were obtained from Carworth Laboratory Animals, Jamaica, N.  ¥. 
The inbred strains, CBA/J and AKR, were purchased from Jackson Laboratories, Bar Harbor, 
Maine. The AKR mice are C5-deficient. 
Tissue culture medium RPMI-1640  and phosphate-buffered saline (PBS,  Dulbecco)  were 
obtained from Grand Island Biological Co., Grand Island, N. Y. Each was adjusted to pH 7.4. 
Cobra venom factor  (CVF)  was obtained from Cordis Laboratories,  Miami, Fla. Crystallized 
BSA was obtained from Pentex Biochemicals, Kankakee, Ili. 
Lyophilized whole guinea pig serum was purchased from Cordis Laboratories. C4-deficient 
guinea pig serum was given to us by Dr. Ira Green. A unique, genetically C3-deficient human 
serum  (30),  having normal  C3-inactivator activity, was a  gift from  Doctors  F.  Rosen and 
C. Alper. 
A pool  of mouse antiserum to BSA was obtained by injecting CBA mice in the hind foot- 
pads with 250 #g of BSA in complete Freund's adjuvant (0.06 ml per mouse), and bleeding 
4 wk later. All sera were stored at  --70°C. 
Purified  human C3  (2  mg/ml) and C3b  (1  mg/ml) were gifts from Dr.  V.  Bokisch. The 
C3b was isolated from trypsin-treated  C3.  Both solutions were dialyzed against PBS  before 
use. Sheep erythrocytes sensitized with antibody (EA) were prepared as in (4). 
Labeling of BSA with 12'~I.--Carrier-free Na  I12'5I] in 0.1  M  NaOH, 325  mCi/ml, was ob- 
tained from New England Nuclear, Boston, Mas;. The BSA was iodinated by the method of 
Hunter and Greenwood (3, 31). After iodination the protein solution was extensively dialyzed 
against saline and centrifuged at 20,000 g for 30 min. The final preparation had an activity of 
about 2  )<  106 cpm//~g protein, and was stored at --70°C. 
Complex Coated Lymphocytes.--Soluble immune complexes were prepared  as described be- 
fore (3)  by mixing 5  ml of [I2~I]BSA, 5/~g/ml, with  1 ml of mouse anti-BSA serum, diluted 
1:2.  The proportion  between  antigen and  antibody for  optimal  binding was found by pre- 
liminary titration  to be close to equivalence. After an incubation of 30 rain at 37°C, 0.25 ml 
of fresh mouse serum  (as a  complement source) was added,  and the complexes incubated a 
further  30  min  at  37°C.  The complexes were  then  mixed with washed  mouse lymph node 
cells, 0.5  ml of complexes per milliliter  of cell  suspension containing 5  X  107  cells/ml, and 
incubated for 40 min at room  temperature.  The complex-coated cells were  then washed  by 
centrifugation  to  remove  unbound  complexes,  and  resuspended  to  a  concentration  of  l0 s 
cells/ml. Under these conditions, the cells bind about 30~ of the 12 ~'I-labeled BSA incorporated 
into the complexes. 
Release ~[ Cell-Bound Complexes.--Aliquots of 0.05 ml of the compIex-coated cell suspension 
were added to  12  X  75 mm tubes (5  M  106  cells per tube). To each tube was added 0.2 ml 
of a  dilution of fresh mouse or guinea pig serum, or medium alone as a  negative control. The 
guinea pig serum was first absorbed with CI,'I  mouse spleen cells at 0°C.  5 ml of cold serum 
were added to a pellet of washed cells prepared from the spleens of three mice and the absorp- 
tion allowed  to proceed for 30 rain in an ice bath.  AII  dilutions were made either in RPMI 
medium or  PBS  at pH  7.4.  (It  was found  that  buffers containing Tris,  Veronal,  or Hepes 
inhibited the release activity). 
So  that  the complex release in each tube would begin simultaneously, the cells and sera 
were precooled in ice, since the release is completely inhibited at 0°C. The tubes were then 
incubated for  the desired  time at 37°C, with periodic  shaking. Then the tubes were placed 
into  an  ice  bath,  and  2  ml of ice-cold medium added  to  each. The tubes were mixed on a 
vortex mixer, centrifuged, and the radioactivity of the pellets and supernatants measured in a 
gamma counter. 
Auloradiography.  Mouse lymph node cells coated  with  12~I-labeled immune complexes, 
or the same cells after complex release by serum, were pelleted by centrifugation, and suspended 
in a  few drops of 1~,)~ fetal calf serum in RPMI.  The cells were centrifuged onto microscope G.  MILLER~  P.  SALUK~  AND  V.  NUSSENZWEIG  497 
slides by means of a  cytocentrifuge  (Shandon  Southern  Instruments Inc.,  Sewickley, Pa.). 
The slides were dipped in Kodak NTB-2  emulsion (Eastman Kodak Co., Rochester, N. Y.), 
exposed for 4  wk, developed with Kodak  D-t9 developer, and stained with MacNeal  tetra- 
chrome. Cells showing 10 or more grains were counted as positive. 
51Cr Labding of Mouse Lymphocytes.--SICr as Na2  51CrO4,  1 mCi/ml in saline, was ob- 
tained from New England Nuclear.  The mouse lymph node cells were labeled with  51Cr,  at 
the same time that they were binding the preformed immune complexes, by adding sufficient 
Na2 51CRO4 to the mixture to get a final concentration of 100 #Ci/ml. The cell suspension was 
incubated at 37°C for 30 nfin and washed by centrifugation. The 51Cr activity of the washed, 
labeled cells was about 10 5 cpm/10 6 cells. 
Purification of Factor B.--Factor B  (or C3PA)  was  obtained  from guinea  pig serum as 
described in  (32).  The purification was monitored by using a  rabbit antiserum  specific for 
guinea pig factor B, which was a gift from Doctors V. Brade and M. Mayer. Briefly, the pro- 
cedure consisted of (a)  fractionation of a  crude pseudoglobulin fraction on DEAE-cellulose 
and  (b) passage of the active fractions from the previous step on CM-cellulose and then  on 
Sephadex QAE-AS0. A good resolution of peaks in the latter step was obtained. In  the peak 
which had factor B  activity, one major and two minor bands were detected by disk electro- 
phoresis in acrylamide gel. The identity of the bands was established by longitudinally slicing 
the gel after the run and  (a)  staining half with amido-schwartz, (b)  assaying the other half, 
imbedded in an agarose plate,  by double diffusion against rabbit antisera specific for factor 
B  and for whole guinea pig serum. The major band reacted with anti-factor B  serum,  and 
one of the minor bands was identified as immunoglobulin. 
RESULTS 
Release of Cell-Bound Complexes by Serum. Kinetics and Effect of Dilution.- 
Mouse  lymph node lymphocytes were  incubated with  [12~I]BSA, mouse  anti- 
serum to BSA and fresh mouse serum as a source of complement, as described 
in the Methods section. After this treatment,  20-30% of the cells  (B lympho- 
cytes) bind the complexes. The cells were subsequently washed by centrifuga- 
tion and reincubated at 37°C in fresh mouse serum. About 80% of the labeled 
BSA was released from the cells in 20 rain. Thereafter little additional release 
occurred (Fig.  1). Autoradiographs of the lymphocytes after serum treatment 
showed  that  a  substantial  portion  of  the  remaining  complexes  was  trapped 
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FIG.  1. Release of immune complexes from surface of CF1  lymph node cells by undiluted 
CFI  mouse serum at 37°C,  after  the standard release procedure described in  the Methods 
section. Each point represents the mean of three tubes. The vertical bars show standard errors. 498  COMPLEMENT-DEPENDENT  RELEASE  OF  IMMUNE  COMPLEXES 
within small clumps of ceils. However, a few heavily-labeled cells (less than 1% 
of the total) were still present. The remaining cell-associated complexes, which 
could not be removed by further addition of serum, had not been ingested by 
the cells,  since they could be removed by subsequent  treatment with  excess 
BSA, as described in reference (24). 
The release activity, which is also found in human, rat, and guinea pig serum 
(Fig.  2),  is very sensitive to dilution. It is slowed down and incomplete when 
cells are incubated in less than about 10 % of serum. The activity diminishes at 
temperatures below 37°C, and is completely inhibited at 0°C. 
Condition  of  Released Complexes  and  of  Cells after Release.--The  serum- 
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FIG. 2. Effect of serum dilution upon kinetics of immune complex release. The complexes 
were  released from  CF1  mouse lymph node  cells at  37°C  by guinea pig  serum diluted  in 
RPMI.  The guinea pig serum was previously absorbed with CF1  spleen cells at 0°C.  Each 
point represents the mean of two tubes. The vertical bars show standard errors. 
extensive enzymatic degradation of the antigen because th@2~I]BSA  which  is 
released can be precipitated by 50 % saturated ammonium sulfate, and is com- 
pletely eluted within the void volume when passed through a column of Sepha- 
dex G-200. However, an important change in the complexes is evident, as they 
will no longer bind to fresh lymphocytes. The lack of binding is not caused by 
the generation of an inhibitor of binding, unless the inhibitor has a molecular 
weight in excess of 200,000 daltons, since partially purified removed complexes 
which are eluted in the void volume of a Sephadex G-200 column are  entirely 
inactive. 
We have considered the possibility that  the  complex release is  simply the 
result of cell damage mediated by complement; this does not appear to be the 
case because release is  not  accompanied by cell damage  measurable  by  51Cr 
release or by Trypan blue exclusion (Table I). Furthermore, complexes are not G.  MILLER,  P.  SALUK,  AND  V.  NUSSENZWEIG  499 
released  from  the  membrane  when  the  cells  are  disrupted  by  freezing  and 
thawing three times. 
Complement Dependence of Complex Release.--The  release  activity is  totally 
inhibited  in  the presence of 0.01 M  Na3H EDTA or by heating  the serum at 
50°C for 30 min.  These results suggested  that complement might be involved 
in this process,  and this was confirmed by subsequent  findings. The release is 
abolished by pretreatment of the serum with insoluble immune complexes such 
as sheep  erythrocytes coated  with  anti-erythrocyte  antibodies,  or  BSA-anti- 
BSA precipitates prepared at equivalence. 
One key component of serum involved in the release activity is C3, because 
(a) treatment of serum with CVF abolished its activity. 1/~ ml aliquots of CF1 
mouse serum, diluted 1:4, were mixed with 0.05 ml of threefold serial dilutions 
TABLE I 
Absence of Lymphocyte Damage Measurable by  51Cr Release after lmune  Complex Removal 
with Serum 
Experiment  Treatment of aWr-labeled, complex-coated  ~ICr released  Complexes released 
no.  mouse lymphocytes*  (-t-SE)  (+SE) 
%  % 
CF1 mouse serum, dil. 1:2  14.3  4-  0.6  73.4  4-  3.2 
RPMI  13.8  -t- 0.4  7.2  4-  0.4 
Freeze and thaw 3X  78.8  -4- 0.5  12.0  -4- 0.6 
2  Guinea pig serum, dil. 1:2  12.8  -4- 0.7  50.8  -4-  1.2 
RPMI  12.2  -4-  1.4  8.2  4-  0.3 
* The cells were incubated with serum or RPMI for 30 rain at 37°C. The guinea pig serum 
was previously absorbed with mouse spleen cells at 0°C. 
of CVF ranging from 1:10 to  1:2,430.  The mixtures  were incubated  at 37°C 
for 30 rain,  and kept in an ice bath until  assayed. A  50 %  inhibition of release 
was obtained  with  a  CVF dilution  of 1:550  and  the  activity was completely 
abolished by CVF at 1:90. (b) A unique genetically C3-deficient human serum 
is  devoid of activity,  but  it  can  be  made  active  by  the  addition  of purified 
human  C3  (Fig.  3).  However,  purified  human  C3b  fragments,  obtained  by 
trypsin hydrolysis of C3, could not activate the C3-deficient serum. By them- 
selves, C3, C3b, or a mixture of C3 and C3b were totally inactive. Components 
further  in  the  complement sequence  than  C3  probably are  not necessary be- 
cause the release activity is observed in C5-deficient mouse serum. 
The  release  activity  can  be  generated  through  the  alternate  pathway  of 
complement fixation. Serum from C4-deficient guinea pigs is active, and release 
requires  Mg  ++ but not Ca +  ions. Sufficient EGTA to chelate both Ca  ++ and 
Mg  ++ ions completely inhibits the release; this can be totally restored by adding 
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FIG. 3. Activation of  genetically C3-deficient human serum for immune complex release 
by addition of purified human C3. To tubes containing 5  X  106 complex-coated CF1 mouse 
lymph node ceils, kept in an ice bath, were added 50 #1 of serum, various amounts of purified 
C3 or C3b, and sufficient PBS to give a  total volume of 0.25 ml. The release of complexes was 
allowed  to proceed for 30 mix at 37°C. The original  concentrations of the purified  C3  and 
C3b were 2 mg/ml and 1 mg/ml, respectively. Each point represents the mean of two tubes. 
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Fla.  4.  Time-course  of  immune complex  release  from  CF1  mouse lymph  node  cells, 
using normal  CF1  mouse serum  (top)  or  C4-deficient guinea pig  serum  (bottom),  in  the 
presence or absence of Ca  ++. The mouse serum was diluted 1:5 in PBS. The guinea pig serum 
was diluted 1:4, and was previously absorbed with CF1 mouse spleen cells at 0°C. Sufficient 
EGTA was added to a portion of each serum to chelate all of the Ca  ++ present (as determined 
in control experiments involving lysis of EA). MgCI was added to all sera to ensure an excess 
of  Mg  ++.  Final  concentrations of EGTA  and  MgCI  in  the  mouse serum were  2  mM  and 
2.5 raM, respectively, and in the guinea pig serum, 1.5 mM and 2.0 raM. For the guinea pig 
serum each point represents the mean of two tnbes. The vertical bars show standard errors. G.  MILLER~  P.  SALUK,  AND  V.  NUSSENZWEIG  501 
clarify this point. In the presence of excess Mg  ++,  the rate of release of com- 
plexes with  C4-deficient guinea pig serum or with  mouse serum was  not re- 
duced in the presence of sufficient EGTA to chelate all of the Ca  ++.  We have 
also found that a  concentration of  Ca  ++ ions in excess  of 2  mM inhibits the 
release.  Another indication of  the  participation of  the  alternate pathway in 
the complex release is that purified factor B  completely restores  the  activity 
of  heat-inactivated  C4-deficient  guinea  pig  serum  (Fig.  5).  Normal  serum 
behaved  differently  from  C4-deficient  serum  in  this  experiment;  a  higher 
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FIG. 5. Restoration with purified factor B (C3 proactivator) of the release activity of heat- 
inactivated  (50°C, 30 rain) normal or C4-deficient guinea pig sera. The sera were previously 
absorbed with CF1 mouse spleen cells. To tubes containing 5 X  106 complex-coated CF1 
mouse lymph node cells, kept in an ice bath, were added 50/~1 of normal serum or 75 #1 of 
C4-deficient serum, various amounts of purified guinea pig factor B (OD2s0 .... 1 em =  1.16), 
and sufficient PBS to give a total of 0.25 ml. The complex removal was allowed to proceed 
for 45 min at 37°C. The heat-inactivated sera had no release activity, as compared with PBS 
controls. The unheated normal serum gave 32.5% specific (PBS control subtracted)  release; 
the unheated C4-deficient serum gave 39.6% specific release. The amount of factor B added is 
plotted as microliters per 75 #1 of serum. Each point represents the mean of two tubes. The 
vertical bars show standard errors. C4-deficient serum, O--O ; normal serum, 0--[2]. 
concentration of  factor  B  was  necessary to  restore  release  activity to  heat- 
inactivated normal serum (Fig. 5). One possible explanation for this difference 
is that in normal serum the classical complement pathway is simultaneously 
triggered by the  complex-coated cells and inhibits the release activity of  the 
alternate pathway, perhaps by competing for C3. 
Experiments were also performed to determine whether the release activity 
behaved in the manner of a stable enzyme, that is, without being consumed or 
modified during the reaction. Complexes were removed from lymphocytes with 
guinea pig serum or mouse serum at 37°C for 30 min. The supernatants, which 
contained the inactive removed complexes, were then added to tubes containing 502  COMPLEMENT-DEPENDENT  RELEASE  OF ~IMUNE  COMPLEXES 
fresh, complex-coated lymphocytes. No further removal of complexes was ob- 
served. A  sample of guinea pig serum which was simultaneously incubated at 
37°C retained its full potency. Thus, this experiment suggests that if a removal 
enzyme is generated, it becomes inactive in a matter of minutes at 37°C, and/or 
a substrate which is necessary for removal is used in the reaction. 
DISCUSSION 
The main new findings of this paper are that  (a)  certain membrane-bound 
immune complexes can be released by serum and (b)  the complement system 
plays a central role in this phenomenon. The present data were obtained in a 
convenient in vitro experimental model, in which the cells bearing the complexes 
were lymphocytes. 
We have also obtained evidence that a similar mechanism probably operates 
in  vivo.  3 When  soluble  immune  complexes were  injected intravenously  into 
mice, they were rapidly picked up by circulating cells (mainly platelets)  and 
within minutes released into the plasma. In contrast, complexes which had been 
previously released in vitro from the membranes of lymphocytes did not bind 
to the platelets. These findings suggest that the regulation by complement of the 
interaction between immune complexes and cell membranes may be operative 
for other cell types (such as mouse platelets) which have C3 receptors on their 
surfaces. 
It is interesting that C3, which presumably is the link connecting the com- 
plexes to the plasma membrane, also appears to play a key role in their libera- 
tion from the cell surface. Such a  dual role for C3 is not novel; for example, 
the activation of the alternate pathway by C3b, itself a product of complement 
utilization, has been described (33,  34). The release of complexes involves the 
alternate pathway of complement fixation, but its mechanism is not yet under- 
stood at  the  molecular level. The following possible mechanisms  of complex 
release should be considered. 
(A)  C3  conversion products,  generated when fresh serum is  added  to  the 
complex-coated cells, could compete with the complexes for the C3 receptors on 
the cell membrane. This cannot be the sole explanation for our findings because, 
in addition to being released, the complexes simultaneously lose their affinity 
for the cell membrane of lymphoid cells in vitro, as well as their capacity for 
binding to mouse platelets in vivo. Moreover, (a) Purified human C3b or C3 
conversion products generated in mouse or guinea pig serum by treatment with 
EA, immune precipitates, or CVF are entirely ineffective for complex release. 
(b)  EAC1423  prepared with  human  complement components, and known  to 
have C3b on their surfaces, do not bind to mouse lymphocytes (35); that is, 
mouse  lymphocytes have  no  binding  sites  for human  C3b,  and  yet human 
serum is effective for complex release. These findings render unlikely a competi- 
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tive mechanism for release, unless one postulates unique binding properties for 
nascent C3 conversion products. 
(B) An enzymatic activity, generated through the alternate pathway, might 
modify the complex-bound C3 and inactivate its binding site for the cell mem- 
brane. At least three serum enzymes are known to modify C3 or C3 products. 
Two of them, C42 and C3 activator, are short-lived at 37°C and are known to 
act upon native C3 (36, 37).  The third enzyme, C3 inactivator (or KAF) (38- 
40),  which acts upon C3b and generates two other fragments, C3c and C3d 
(41),  can be excluded as being responsible for the release of complexes for the 
following reasons: (a) C3ina is not generated by complement activation, but is 
preformed in serum. (b) C3ina is neither thermolabile nor dependent upon ions 
for its activity.  (c)  A  C3-deficient serum which does not remove complexes 
possesses  normal  C3ina  activity (30).  (d)  We  have  recently found  that  B 
lymphocytes, in contrast to granulocytes, have receptors not only for C3b but 
also for the complement fragment (C3d) generated by the activity of C3ina on 
C3b.  4 In other words, C3ina should be ineffective for the release of immune 
complexes bound to lymphocytes by means of C3b because the product which 
is generated through the activity of C3ina on C3b retains its affinity for the cell 
surface. 
(C)  Products  generated  through  the  alternate  pathway might  block  the 
expression of the binding sites on the immune complexes for the cell membrane. 
There is a precedent for this hypothesis in the observations of Blum (42) and of 
Koethe et al. (43), who noticed that the activation of the complement sequence 
through the alternate pathway with zymosan or CVF generates products which 
block the lysis of hemolytic cellular intermediates obtained by the  classical 
complement sequence. According to this hypothesis, when the antigen-antibody- 
complement complexes are prepared, the classical pathway is activated and a 
C  component with  binding activity for B  lymphocytes is  incorporated into 
the complexes.  Later, after the incubation of complex-coated cells  in a  high 
concentration of fresh serum,  products  of the  alternate pathway modify or 
cover the C3 binding sites on the complexes,  and these are released and simul- 
taneously deactivated. Whatever the explanation for the complex release, this 
system provides a convenient assay for the functioning of the alternate com- 
plement pathway in the mouse and in other mammalian species. 
Our findings indicate that complement can regulate the interaction between 
immune complexes and the membranes of leukocytes. In these experiments, 
binding and release of complexes have been artificially, though conveniently 
separated.  In  a  physiological situation,  in  which  complement is  constantly 
available,  its  interaction with antigen-antibody complexes may sequentially 
produce intermediates whose binding affinities for cell membranes first increase 
and then decrease within a short time. In this context it would be interesting to 
4 Eden, A., G. Miller, and V. Nussenzweig. Manuscript submitted for publication. 504  COMPLEMENT-DEPENDENT  RELEASE OF  IMMUNE COMPLEXES 
verify whether  a  transient  contact between  these  immune  complexes and  the 
cell  membrane  can  trigger  effector mechanisms  such  as  the  release  of vaso- 
active  amines  from platelets.  Finally,  our  findings  raise  the  interesting  pos- 
sibility that alterations in the complement system leading to a defective release 
mechanism may be implicated in the pathogenesis of immune complex diseases. 
SUMMARY 
Soluble antigen-antibody-complement complexes bound to mouse B lympho- 
cytes are  rapidly  released  from the  cell  membrane  in  the  presence  of normal 
serum from several mammalian species. The release is not the result of antigen- 
antibody dissociation or extensive degradation of the complexes. However, the 
released complexes have been altered because they will no longer bind to fresh 
lymphocytes. The release is not the result of lymphocyte damage mediated by 
complement. It is complement-dependent, and is generated either preferentially 
or exclusively via the alternate pathway, since it occurs in C4-deficient serum, 
is Mg  ++ but not Ca  ++ dependent,  and requires C3 proactivator. C3 inactivator 
is not involved. The release  activity of the serum,  once generated, is unstable 
at 37°C. The release  of complexes from the  lymphocyte merabrane  by serum 
provides a convenient assay for the functioning of the alternate pathway in the 
mouse and in other species. 
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